drugset / Trial / NCT01213173

Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients

NCT01213173

Phase 4 Completed 251 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of Succinate Metoprolol(Betaloc ZOK®) (95 - 190 mg) on heart rate in the Stable angina patients.

Timeline

Start
2010-10
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified 95 mg
Subject Metoprolol Other / unclassified 190 mg

Indications

No indication recorded.